KEY DETAILS
Maine signed LD 1970 into law on March 19, 2026, an act on consent for HIV testing and disclosure of related medical information for insurance purposes.
A Stanford University trial on post-bariatric hypoglycemia, not yet recruiting, plans to test diet, a GLP-1 or dual GIP/GLP-1 receptor agonist, and TORe.
The EMA published an update on October 16, 2026 describing a once-daily oral GLP-1 tablet as an alternative to other oral and injectable GLP-1 medicines.
GLP1Laws tracked three developments on Saturday, October 17, 2026, spanning state legislation, clinical research, and a regulatory update from Europe's medicines agency. Together they touch on insurance disclosure rules, a planned trial for a surgery-related complication, and a European agency update about an oral GLP-1 medicine.
Maine signed LD 1970 into law on March 19, 2026, which was several months before this roundup, so this is background rather than fresh news. The act amends the state's laws on consent for HIV testing and on disclosure of related medical information for insurance purposes. It had 10 sponsors, and its status is listed as signed by the governor. Its title concerns HIV testing consent and insurance disclosure and does not mention GLP-1 medicines.
Stanford University has registered a clinical trial for post-bariatric hypoglycemia, a complication of upper gastrointestinal surgery. The trial is not yet recruiting, so there are no results to share. It plans to evaluate three approaches: dietary modification, treatment with a GLP-1 receptor agonist or a dual GIP/GLP-1 receptor agonist, and a procedure called transoral outlet reduction (TORe). Its listed enrollment is 30 people, its listed start date is November 1, 2026, and completion is listed for November 2031.
The European Medicines Agency posted an update on October 16, 2026 about a new oral GLP-1 medicine for weight management and type 2 diabetes. The agency describes it as a once-daily tablet that provides an alternative to other oral and injectable GLP-1 medicines. The update as listed does not name the medicine or give details on pricing, availability, or approval conditions.
You can find the full record for each of these three items on glp1laws.com, with the original sourcing and dates included.
Originally published on GLP1Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.